Search Results

An Open-Label Multiple-Dose, 52-Week Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents (ages: 12 to <18 years) with Conditions Associated with Deficiency or Absence -STUDY00005089

The objectives of this study are: • To determine the efficacy of XYOSTED administered at an appropriate dose and interval to permanently...

Daniel J Crawford, MD

Daniel J Crawford, MD, Acting Assistant Professor

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care / (POPS): NICHD-2019-POP02-STUDY00002420

Prospective, multicenter study of understudied drugs. Participants will receive drugs of interest administered per standard of care. Primary:...

Phase 1b/2, randomized, double-blind, placebo-controlled, multi-center study of STMC-103H in neonates and infants at high-risk for developing allergic disease-STUDY00003212

Primary indication is to see is STMC-103H, prevents allergic disease in at-risk neonates. The primary objective of this study is to assess the...

Anna Rose Forsyth, DDS

Anna Rose Forsyth, DDS

Florence Omoro Smith, ARNP

Florence Omoro Smith, ARNP

Amber Michelle Rogers Bock, ARNP

Amber Michelle Rogers Bock, ARNP specializing in Hospital Medicine, Urgent Care

Andrew Daniel Linkugel, MD

Andrew Daniel Linkugel, MD specializing in Craniofacial Center

Resiliency in Families Affected by Congenital Heart Disease-STUDY00002036

To learn more about this study, please email the study team member listed below.

A Post-Authorization Safety Study (PASS) to Assess Long-term Safety in Patients with Pompe Disease Treated with Avalglucosidase alfa in the Real-World Setting: the SAVANT (Safety assessment of AValglucosidase Alfa as a Novel Treatment) study-STUDY00005276

To collect long term safety data and evaluate the important identified risk of infusion associated reactions (IARs) including hypersensitivity and...